RomânăFără categorie
Genomic Tests in Cancer: A Complete Guide for Patients – What They Are, How They Work, and How They Can Change Your Treatment
If you have recently received a cancer diagnosis or are closely following the journey of a loved one through this disease, you may have come across terms like “genomic test,” “molecular tumor profile,” or “recurrence score.” These concepts can seem overwhelming, especially at a time when emotions are running high. But here’s the good news: genomic tests represent one of the most important revolutions in modern oncology and can make the difference between a generic treatment and a personalized one, tailored exactly to the biology of your tumor. This guide was created to explain, in simple and clear words, what these tests are, which forms of cancer they apply to, and how they can concretely influence your doctor’s decision regarding chemotherapy, immunotherapy, or targeted therapy.
What Are Genomic Tests and How Do They Differ from Classic Genetic Tests?
Many patients confuse tumor genomic testing with hereditary genetic testing. Here is the essential difference, explained simply:
- Hereditary genetic tests (such as HerediGENE or the BRCA1/BRCA2 test) analyze DNA from healthy cells in your body—usually from blood or saliva—to detect inherited mutations that increase your risk of developing cancer over time. They answer the question, “Have I inherited a genetic predisposition to cancer?”
- Tumor genomic tests analyze the DNA or RNA from actual cancer cells , not healthy cells. They answer another, equally important question: “What is my tumor doing biologically, and how can it be most effectively fought?”
Basically, genomic tests “read” the activity of genes in the tumor and can predict its behavior: how aggressive it is, how high the risk of recurrence is, and whether a certain treatment (chemotherapy, targeted therapy, immunotherapy) will be effective. According to the international NCCN and ESMO guidelines, these tests are recommended in more and more types of cancer, becoming an integral part of modern therapeutic decision-making.
Genomic Testing in Breast Cancer: The Example of Oncotype DX
The best-studied and used genomic test in the world is the Oncotype DX Breast Recurrence Score® , recommended in early-stage, hormone receptor-positive (HR+) and HER2-negative invasive breast cancer.
How Does It Work?
The test analyzes the expression of 21 genes in tumor tissue collected from a biopsy or surgery. The result is a number between 0 and 100, called the Recurrence Score® , which provides three essential pieces of information:
- Risk of distant recurrence – the likelihood that the tumor will return in other organs (lungs, bones, liver) within the next 10 years
- Absolute benefit of chemotherapy – how much chemotherapy reduces this risk
- Biological aggressiveness of the tumor – an indicator of cancer cell behavior
How to Interpret the Result?
| Recurrence Score | Meaning | Therapeutic implication |
| 0–25 | Low to intermediate genomic risk | Hormonal therapy is usually sufficient; chemotherapy does not provide significant benefit. |
| 26–100 | High genomic risk | Adding chemotherapy to hormonal therapy brings important benefit |
A key point: for premenopausal patients with a score between 16 and 25, the decision is more nuanced and depends on age, tumor size, and lymph node status. The TAILORx and NSABP B-20 clinical trials , conducted on tens of thousands of patients, have validated the utility of this test and are the basis for clinical interpretation.
Why it matters? Oncotype DX has shown that many patients with early-stage breast cancer can safely avoid chemotherapy —with all its side effects (nausea, hair loss, fatigue, risk of infection)—without compromising their chances of a cure. Conversely, patients with high scores actually benefit from more aggressive treatment.
Genomic Testing in Colorectal Cancer
In colorectal cancer, genomic approaches have evolved significantly. The Com.PLiT DX® Colon test is an example of a noninvasive screening test that detects abnormal DNA markers in feces and can be performed at home. A positive result (the presence of abnormal DNA markers) is a signal that a confirmatory colonoscopy is required.
In addition to screening, in diagnosed colorectal cancer, tumor molecular profiling is essential to decide whether the patient can benefit from:
- Anti-EGFR targeted therapies (cetuximab, panitumumab) – exclusively in tumors with wild-type (non-mutant) RAS/RAF status
- Immunotherapy (pembrolizumab) – in tumors with high microsatellite instability (MSI-H)
KRAS, NRAS, BRAF mutations and MSI status is today part of standard oncological practice in metastatic colorectal cancer, according to international guidelines.
Genomic Testing in Prostate Cancer and Melanoma
Prostate Cancer
Com.PLiT DX® Prostate test combines molecular biomarkers with artificial intelligence algorithms to assess the risk of prostate cancer in peripheral blood. It is complementary to the classic PSA and can reduce the number of unnecessary biopsies, guiding clinical decision-making.
At an advanced molecular level, testing for BRCA1/2 mutations and other genes involved in DNA repair is essential to identify patients with metastatic prostate cancer who may benefit from PARP inhibitors (olaparib, rucaparib) – targeted therapies with demonstrated efficacy.
Melanoma
Com.Plit DX® Melanoma offers immunohistochemical testing on tissue samples (FFPE) or liquids for the detection of melanoma-specific markers .pdf). BRAF V600E mutation testing is standard in metastatic melanoma: patients with this mutation can benefit from targeted therapy with BRAF/MEK inhibitors (vemurafenib, dabrafenib + trametinib), with remarkable responses. Also, PD-L1 expression testing guides the decision for immunotherapy (pembrolizumab, nivolumab).
Genomic Testing in Rare Cancers: Cholangiocarcinoma
Cholangiocarcinoma (bile duct cancer) is a rare cancer with a poor prognosis. The Com.P.LiT DX® Cholangiocarcinoma test is a NGS (next-generation sequencing) panel that detects therapeutically relevant mutations from tumor material (FFPE) or liquid biopsy (plasma ctDNA) .pdf).
The identification of these mutations has opened up new therapeutic perspectives:
- FGFR2 fusions – patients with this alteration can receive specific inhibitors (pemigatinib, futibatinib), with clinically proven responses
- IDH1 mutations – treated with ivosidenib
- BRAF, HER2, high TMB mutations – each with specific targeted options
This testing is mandatory in advanced/metastatic biliary cancer, according to the ESMO 2024 guidelines, to access therapies that can significantly prolong survival .pdf).
Liquid Biopsy – The Revolution in Cancer Monitoring
A revolutionary concept in current oncology is liquid biopsy – the analysis of circulating tumor DNA (ctDNA) or circulating tumor cells (CTC) directly from the blood, without requiring an invasive tissue biopsy.
RGCC (Research Genetic Cancer Center) tests are an advanced example of liquid biopsy that:
- Isolates circulating tumor cells from the blood through advanced techniques (flow cytometry)
- Tests in vitro the sensitivity of cancer cells to dozens of chemotherapeutic agents and targeted therapies
- Provides a real-time molecular profile of the tumor
Interpretation of the number of circulating tumor cells (CTC) :
- Below 3 CTC/mL → low risk (corresponding to an early stage)
- 3–20 CTC/mL → moderate risk (stage II-III)
- Over 20 CTC/mL → high risk, active disease (stage IV/metastatic)
Liquid biopsy allows for continuous monitoring of the disease , sometimes detecting recurrence months before it is visible on imaging. It is particularly useful for monitoring response to treatment and early detection of tumor resistance. Important: according to international guidelines, liquid biopsy results should always be interpreted in a clinical context, alongside imaging and pathological examination.
What Does a “Positive” or “Negative” Result Mean on a Genomic Test?
Unlike a regular blood test where “positive” means the presence of a marker, in tumor genomic tests the interpretation is more nuanced:
- Identifying an actionable mutation = a therapeutic opportunity. It means your tumor has a specific vulnerability that a targeted therapy can exploit
- Absence of tested mutations = there is no specific molecular target in the tested panel, but standard treatment may still be effective
- Variants of uncertain significance (VUS) = mutations identified, but whose clinical impact is not yet fully clarified; requires further monitoring and evaluation
📊 Complete Table: Genomic Tests in Cancer – Visual Guide for Patients
TABLE 1: Difference between Hereditary Genetic Test and Tumor Genomic Test
| 🧬 Hereditary Genetic Test (ex: HerediGENE, BRCA) | 🔬 Tumor Genomic Test (ex: Oncotype DX, NGS) | |
| What is it analyzing? | The DNA in the HEALTHY cells of your body | DNA from CANCER tumor cells |
| Where is the sample collected from? | Blood or saliva | Tumor tissue (biopsy) or blood (liquid biopsy) |
| What question does it answer? | “Have I inherited a genetic risk of cancer?” | “How is my tumor doing and what treatment is working?” |
| Who does the test? | Any person, even healthy | Patients with already diagnosed cancer |
| Test example | HerediGENE, BRCA1/BRCA2 | Oncotype DX, NGS panels .pdf) |
| The result helps… | Prevention, monitoring, family decision | Choosing chemotherapy, targeted therapy, immunotherapy |
TABLE 2: Oncotype DX – The Most Used Genomic Test in Breast Cancer
| Recurrence Score (0–100) | What does this mean? | Risk of recurrence | Chemotherapy recommended? |
| 0 – 15 | Very low genomic risk | Low | ❌ Usually NO – hormone therapy is sufficient |
| 16 – 25 | Intermediate genomic risk | Moderate | ⚠️ DEPENDS on age and the condition of the lymph nodes |
| 26 – 100 | High genomic risk | High | ✅ YES – chemotherapy brings significant benefit |
💡 Important note for young patients (under 50): Scores of 16–25 require a nuanced discussion with the doctor, as age and menstrual status influence the decision
TABLE 3: Genomic Tests by Cancer Type – Quick Guide
| Cancer Type | Available Test | What Does It Detect? | How Does Treatment Change? |
| 🎗 ️ Breast Cancer | Oncotype DX Breast Recurrence Score®-Genekor | Activity of 21 genes in the tumor | Decide whether chemotherapy is necessary or can be safely avoided |
| 🎗 ️ Breast Cancer | Com.PLiT DX® Breast- Genekor | Circulating blood proteins | Differentiates benign from malignant lesions; reduces unnecessary biopsies |
| 🟤 Colorectal Cancer | Com.PLiT DX® Colon- Genekor | Abnormal DNA markers in feces | Early detection; positive result → confirmatory colonoscopy |
| 🔵 Prostate Cancer | Com.PLiT DX® Prostate- Genekor | Molecular biomarkers in blood + AI | Guides biopsy decision; complementary to classic PSA |
| 🟡 Biliary Cancer (Cholangiocarcinoma) | Com.P.LiT DX® Cholangiocarcinoma- Genekor | FGFR2, IDH1, BRAF, TMB mutations (NGS) | Identify whether the patient can receive specific targeted therapies (.pdf) |
| ⚫ melanoma | Com.Plit DX® Melanoma- Genekor | Specific protein markers (IHC) on tissue | Detects BRAF V600E mutation → indicates BRAF/MEK inhibitors (pdf ) |
| 🔴 Lung Cancer | Com.PLiT DX® Lung- Genekor | Lung-specific mutations | Guides targeted therapy and immunotherapy |
| 🟠 GIST / GI Tumors | Com.PLiT DX® GIST- Genekor | Tissue or fluid molecular markers | Comprehensive assessment of tumor response (pdf) |
TABLE 4: RGCC Liquid Biopsy – Interpretation of Circulating Tumor Cell (CTC) Count
| CTC count/mL blood | Clinical Significance | Corresponding Stage | What’s next? |
| Below 3 CTC/mL | Low risk | Stage I (early) | Periodic monitoring |
| 3 – 20 CTC/mL | Moderate risk | Stage II–III | Imaging evaluation + treatment adjustment |
| Over 20 CTC/mL | High risk, active disease | Stage IV (metastatic) | Intensive treatment, frequent monitoring |
⚠️ Important: Liquid biopsy results should always be interpreted in conjunction with imaging (CT, MRI, PET) and clinical examination, not in isolation.
TABLE 5: Types of Genetic Variants Identified – What Does Each Mean?
| Genomic Result Type | What does it mean in simple words? | What does the doctor do? |
| (Pathogenic) mutation | The tumor has a specific vulnerability | Prescribe a targeted therapy that attacks exactly that mutation |
| Variant of Uncertain Significance (VUS) | Mutation identified, but impact unclear | Monitoring; possible retesting or further studies .pdf) |
| No mutations in the tested panel | No specific molecular target found | Standard treatment remains an effective option |
| MSI-H (Microsatellite Instability High) | The tumor has a special DNA repair defect | Ideal candidate for immunotherapy (pembrolizumab) |
| High TMB (Tumor Mutational Burden) | The tumor has many accumulated mutations | Possible benefit of immunotherapy |
| FGFR2 fusion (cholangiocarcinoma) | The genes have “stuck” together abnormally | FGFR2 inhibitors (pemigatinib, futibatinib).pdf) |
| BRAF V600E mutation (melanoma, colorectal) | A specific gene is permanently activated | BRAF/MEK inhibitors (vemurafenib, dabrafenib) |
TABLE 6: Quick Comparison – Genomic Testing Methods
| Criterion | Tissue Biopsy (FFPE) | Liquid Biopsy (blood) |
| How is it harvested? | Tumor tissue (surgery/biopsy) | Simple – venous blood sample |
| What is it analyzing? | DNA/RNA directly from tumor cells | Circulating tumor DNA (ctDNA) or circulating tumor cells (CTC) |
| How invasive is it? | ⚠️ Medical procedure | ✅ Minimally invasive |
| Processing time | 10–14 business days .pdf) | 7–10 business days |
| When is it useful? | Initial diagnosis, complete molecular profile | Treatment monitoring, early relapse detection |
| Main limitation | Requires sufficient quality tissue | ctDNA may be undetectable in small tumors (pdf) |
| Test examples | Com.P.LiT DX® Cholangiocarcinoma .pdf), NGS | RGCC Onconomics, ctDNA liquid biopsy |
TABLE 7: How OncoExpertAI Can Help You Navigate Genomic Results
| Your Situation | How OncoExpertAI Helps |
| You received an Oncotype DX report and don’t understand the score | AI interpretation of the score in the context of age, stage, and NCCN/ESMO guidelines |
| You have an NGS report with unknown mutations | Automatic identification of available targeted therapies for your mutations |
| Do you want to know if the proposed treatment is the best? | AI-assisted second opinion, based on thousands of international clinical studies |
| You don’t know if your medical record is complete. | Automatic verification of documents required for a correct opinion |
| Are you confused by the terms in your genomic report? | Translation into accessible language + step-by-step recommendations |
📋 Note: All tables above are strictly informative and educational . The interpretation of any genomic test should be done together with your oncologist specialist , in the context of your individual clinical situation. OncoExpertAI provides informational support and AI-assisted second opinion, but does not replace medical treatment.
How Can OncoExpertAI Help You Understand Genomic Test Results?
Genomic tests generate complex reports, full of technical terms and numbers that can be difficult to interpret without oncology expertise. The OncoExpertAI.com platform was created precisely to fill this gap:
- Artificial Intelligence-assisted analysis – our algorithms scan the genomic profile of your tumor and compare it with thousands of clinical studies and updated international guidelines (NCCN, ESMO), identifying in seconds the relevant therapeutic options for your specific mutations
- Second opinion – get additional perspective from molecular oncology specialists before the final treatment decision
- Accessible interpretation – translating complex results into information you understand, so you can actively participate in therapeutic decisions that concern you
Don’t let a genomic report remain just a piece of paper with numbers. Every number and every mutation in that report can mean the difference between a useless treatment and one that is truly effective for you, for your tumor , not for a statistical average.
Have you received a genomic result and don’t know how to interpret it? [Submit your medical record for a second opinion on OncoExpertAI.com →]
Disclaimer: The information in this article is for informational and educational purposes only. It does not constitute a medical diagnosis and does not replace the consultation of an oncologist. Any therapeutic decision should be made in collaboration with your medical team, based on your individual clinical situation. OncoExpertAI provides informational support and AI-assisted second opinion, but does not replace medical treatment.
Dr. Onisim Florin Senior Medical Oncologist | Founder of OncoExpertAI